8QKO image
Entry Detail
PDB ID:
8QKO
EMDB ID:
Title:
Connexin-43 gap junction channel in complex with mefloquine
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-09-16
Release Date:
2024-09-25
Method Details:
Experimental Method:
Resolution:
3.73 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Gap junction alpha-1 protein
Chain IDs:A, B, C, D, E, F, G, H, I, J, K, L
Chain Length:382
Number of Molecules:12
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Mechanism of connexin channel inhibition by mefloquine and 2-aminoethoxydiphenyl borate.
Plos One 19 e0315510 e0315510 (2024)
PMID: 39739741 DOI: 10.1371/journal.pone.0315510

Abstact

Gap junction intercellular communication (GJIC) between two adjacent cells involves direct exchange of cytosolic ions and small molecules via connexin gap junction channels (GJCs). Connexin GJCs have emerged as drug targets, with small molecule connexin inhibitors considered a viable therapeutic strategy in several diseases. The molecular mechanisms of GJC inhibition by known small molecule connexin inhibitors remain unknown, preventing the development of more potent and connexin-specific therapeutics. Here we show that two GJC inhibitors, mefloquine (MFQ) and 2-aminoethoxydiphenyl borate (2APB) bind to Cx32 and block dye permeation across Cx32 hemichannels (HCs) and GJCs. Cryo-EM analysis shows that 2APB binds to "site A", close to the N-terminal gating helix of Cx32 GJC, restricting the entrance to the channel pore. In contrast, MFQ binds to a distinct "site M", deeply buried within the pore. MFQ binding to this site modifies the electrostatic properties of Cx32 pore. Mutagenesis of V37, a key residue located in the site M, renders Cx32 HCs and GJCs insensitive to MFQ-mediated inhibition. Moreover, our cryo-EM analysis, mutagenesis and activity assays show that MFQ targets the M site in Cx43 GJC similarly to Cx32. Taken together, our results point to a conserved inhibitor binding site in connexin channels, opening a new route for development of specific drugs targeting connexins.

Legend

Protein

Chemical

Disease

Primary Citation of related structures